COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,252 Articles (22,733 medRxiv, 8,519 bioRxiv)

Most recent first Previous |  Page 2983: Articles 29821-29830  | Next

Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study
Lane, J. C., Weaver, J., Kostka, K., Duarte-Salles, T., Abrahao, M. T., Alghoul, H., Alser, O., Alshammari, T. M., Biedermann, P., Burn, E., Casajust, P., Conover, M., Culhane, A. C., Davydov, A., DuVall, S. L., Dymshyts, D., Fernández Bertolín, S., Fišter, K., Hardin, J., Hester, L., Hripcsak, G., Kent, S., Khosla, S., Kolovos, S., Lambert, C. G., ver der Lei, J., Londhe, A. A., Lynch, K. E., Makadia, R., Margulis, A. V., Matheny, M. E., Mehta, P., Morales, D. R., Morgan-Stewart, H., Mosseveld, M., Newby, D., Nyberg, F., Ostropolets, A., Park, R. W., Prats-Uribe, A., Rao, G. A., Reich, C., Reps, J., Rijnbeek, P., Sathappan, S. M., Schuemie, M., Seager, S., Sena, A., Shoaibi, A., Spotnitz, M., Suchard, M. A., Swerdel, J., Torre, C. O., Vizcaya, D., Wen, H., de Wilde, M., You, S. C., Zhang, L., Zhuk, O., Ryan, P., Prieto-Alhambra, D.
10.1101/2020.04.08.20054551 — Posted: 2020-04-10 Discussion: Onsite | Offsite
A model to predict COVID-19 epidemics withapplications to South Korea, Italy, and Spain
Webb, G. F., Magal, P., Liu, Z., Seydi, O.
10.1101/2020.04.07.20056945 — Posted: 2020-04-10
Evaluation of nine commercial SARS-CoV-2 immunoassays
Lassauniere, R., Frische, A., Harboe, Z. B., Nielsen, A. C., Fomsgaard, A., Krogfelt, K. A., Jorgensen, C. S.
10.1101/2020.04.09.20056325 — Posted: 2020-04-10 Discussion: Onsite | Offsite
Homologous protein domains in SARS-CoV-2 and measles, mumps and rubella viruses: preliminary evidence that MMR vaccine might provide protection against COVID-19
Franklin, R., Young, A., Neumann, B., Fernandez, R., Joannides, A., Reyahi, A., Modis, Y.
10.1101/2020.04.10.20053207 — Posted: 2020-04-10 Discussion: Onsite | Offsite
The effectiveness of non-pharmaceutical interventions in containing epidemics: a rapid review of the literature and quantitative assessment
Cheatley, J., Vuik, S., Devaux, M., Scarpetta, S., Pearson, M., Colombo, F., Cecchini, M.
10.1101/2020.04.06.20054197 — Posted: 2020-04-10
Data model to predict prevalence of COVID-19 in Pakistan
Qasim, M., Ahmad, W., Zhang, S., Yasir, M., Azhar, M.
10.1101/2020.04.06.20055244 — Posted: 2020-04-10
Anticipating the novel coronavirus disease (COVID-19) pandemic
Kaur, T., Sarkar, S., Chowdhury, S., Sinha, S. K., Jolly, M. K., Dutta, P. S.
10.1101/2020.04.08.20057430 — Posted: 2020-04-10
Signature of State measures on the COVID-19 Pandemic in China, Italy, and USA
Saif, F.
10.1101/2020.04.08.20057489 — Posted: 2020-04-10
Effects of latency on estimates of the COVID-19 replication number
Sadun, L. A.
10.1101/2020.04.07.20056960 — Posted: 2020-04-10
The Immediate Effect of COVID-19 Policies on Social Distancing Behavior in the United States
Abouk, R., Heydari, B.
10.1101/2020.04.07.20057356 — Posted: 2020-04-10 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).